CD20 suicide gene therapy (MolMed SpA)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCD20 suicide gene therapy (MolMed SpA)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionB-lymphocyte antigen CD20 modulators
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsGraft vs Host Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAgc Biologics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAgc Biologics
Active IndicationsN/A
Inactive IndicationsGraft vs Host Disease

Other Information

ATC CodeN/A
Related LinksN/A